Compare CATO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | SPRO |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.9M | 67.0M |
| IPO Year | 1994 | 2017 |
| Metric | CATO | SPRO |
|---|---|---|
| Price | $2.34 | $1.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 51.6K | ★ 839.8K |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.04 | ★ 111.81 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $653,812,000.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.45 | ★ N/A |
| Revenue Growth | 0.62 | ★ 39.24 |
| 52 Week Low | $2.29 | $1.08 |
| 52 Week High | $4.59 | $3.08 |
| Indicator | CATO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 44.31 |
| Support Level | $2.30 | $1.10 |
| Resistance Level | $2.46 | $1.28 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 35.34 | 15.00 |
The Cato Corp seeks to offer quality fashion apparel and accessories at low prices every day, in junior/missy and plus sizes. The Cato concept's stores and e-commerce website feature a broad assortment of apparel and accessories, including dressy, career, and casual sportswear, dresses, coats, shoes, lingerie, costume jewelry, and handbags. Management believes the Company's success is dependent upon its ability to differentiate its stores from department stores, mass merchandise discount stores, and competing specialty stores. The key elements of the Company's business are: Merchandise Assortment, Value Pricing, Strip Shopping Center Location, Customer Service, Credit and Layaway Programs.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.